Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma

Blood

Volumn 121, Issue 23, 2013, Pages 4753-4757

  Usmani, Saad Z ^a   Sawyer, Jeffrey ^a   Rosenthal, Adam ^b   Cottler Fox, Michele ^a   Epstein, Joshua ^a   Yaccoby, Shmuel ^a   Sexton, Rachael ^b   Hoering, Antje ^b   Singh, Zeba ^a   Heuck, Christoph J ^a   Waheed, Sarah ^a   Chauhan, Nabeel ^a   Johann, Donald ^a   Abdallah, Al Ola ^a   Muzaffar, Jameel ^a   Petty, Nathan ^a   Bailey, Clyde ^a   Crowley, John ^b   Van Rhee, Frits ^a   Barlogie, Bart ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; BORTEZOMIB; CD34 ANTIGEN; LENALIDOMIDE; THALIDOMIDE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; DRUG DERIVATIVE; PYRAZINE DERIVATIVE;

ACUTE LEUKEMIA; AGE; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RISK; CHROMOSOME ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; TREATMENT OUTCOME; ACUTE DISEASE; ADOLESCENT; ADULT; CHEMICALLY INDUCED DISORDER; CHROMOSOME ABERRATION; FOLLOW UP; GENETICS; INCIDENCE; LEUKEMIA; MIDDLE AGED; PROGNOSIS; RISK FACTOR; TUMOR RECURRENCE;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CHROMOSOME ABERRATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LEUKEMIA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROMES; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PYRAZINES; RISK FACTORS; THALIDOMIDE; YOUNG ADULT;

MLCS; MLOWN;

EID: 84881078380     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-11-466961     Document Type: Article

References (20)

1. Attal M, Lauwers-Cances V, Marit G, et al; IFM Investigators. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782-1791.
2. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19): 1770-1781.
3. Palumbo A, Hajek R, Delforge M, et al; MM-015 Investigators. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759-1769.
4. Usmani SZ, Sexton R, Hoering A, et al. Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. Blood. 2012;120(8):1597-1600.
5. Barlogie B, Tricot G, Haessler J, et al. Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989. Blood. 2008;111(1):94-100.
6. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354(10):1021-1030.
7. Barlogie B, Anaissie E, van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol. 2007;138(2):176-185.
8. Nair B, van Rhee F, Shaughnessy JD Jr, et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood. 2010;115(21): 4168-4173.
9. van Rhee F, Szymonifka J, Anaissie E, et al. Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. Blood. 2010; 116(8):1220-1227.
10. Cox DR. Regression tables and life tables. J R Stat Soc, B. 1972;34(2):187-202.
11. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar; 50(3):163-170.
12. Usmani SZ. Second primary malignancies and myeloma therapy: fad or fact? Oncotarget. 2012; 3(9):915-916.
13. Colla S, Zhan F, Xiong W, et al. The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. Blood. 2007;109(10): 4470-4477.
14. Fleming HE, Janzen V, Lo Celso C, Guo J, Leahy KM, Kronenberg HM, Scadden DT. Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo. Cell Stem Cell. 2008;2(3): 274-283.
15. Nösslinger T, Tüchler H, Germing U, et al. Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Ann Oncol. 2010;21(1):120-125.
16. Ishikawa H, Tanaka H, Iwato K, et al. Effect of glucocorticoids on the biologic activities of myeloma cells: inhibition of interleukin-1 beta osteoclast activating factor-induced bone resorption. Blood. 1990;75(3):715-720.
17. Gatto S, Ball G, Onida F, Kantarjian HM, Estey EH, Beran M. Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS). Blood. 2003;102(5):1622-1625.
18. Calado RT, Young NS. Telomere diseases. N Engl J Med. 2009;361(24):2353-2365.
19. Usmani SZ. Melphalan Continues to Rock The Myeloma World. Biol Bone Marrow Transplant. 2013;19(5):680-681.
20. Li L, Li M, Sun C, et al. Altered hematopoietic cell gene expression precedes development of therapy-related myelodysplasia/acute myeloid leukemia and identifies patients at risk. Cancer Cell. 2011;20(5):591-605.